000028 国药一致
2025/06 - 中期
人民幣(K¥)
与去年同期
比较
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
营业总收入36,796,598-2.62%74,378,49475,477,48573,443,13768,357,810
减:营业总成本35,955,919-2.88%73,017,47573,277,09771,309,68866,519,747
    其中:营业成本32,864,812-2.31%66,129,20966,425,42664,516,92660,339,298
               财务费用83,179-30.91%239,424204,535189,514212,483
               资产减值损失(4,695)-51.80%(994,532)(17,577)(71,588)(242,905)
公允价值变动收益----(20,675)(15,161)28,871--
投资收益136,126-28.38%241,793237,029139,131292,381
    其中:对联营企业和合营企业的投资收益179,971-20.81%369,703315,446298,527333,397
营业利润926,496-2.36%573,4782,467,4252,306,0691,952,411
利润总额918,113-4.16%575,4692,473,2272,311,0701,974,853
减:所得税费用205,5199.37%338,466514,739539,332447,211
净利润712,594-7.46%237,0041,958,4871,771,7381,527,642
减:非控股权益46,68675.73%(405,490)359,231285,030191,214
股东净利润665,907-10.43%642,4931,599,2561,486,7081,336,428

市场价值指针
每股收益 (元) *1.200-10.45%1.1502.8702.6703.120
每股派息 (元) *----0.3660.6800.8000.600
每股净资产 (元) *32.5862.00%31.74731.29037.66634.861
审计意见 #--标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容